Niv Ad Joins Pulse Biosciences as Chief Science Officer, Cardiac Surgery

Pulse Biosciences Inc. has added to its leadership team, appointing Niv Ad, M.D., as chief science officer, Cardiac Surgery.

“We are excited to have Dr. Ad join the Pulse Biosciences team. His proven track record and expertise will play an integral role in not only our clinical strategy and driving awareness of our technology through scientific data dissemination, but also contributing to the development of our product portfolio for cardiac surgery,” Pulse Biosciences CEO Kevin Danahy said. “We believe two of the top cardiothoracic surgeons in the world, Dr. Niv Ad and Dr. Gansevoort ‘Gan’ Dunnington, committing to join our leadership team after firsthand experience with nsPFA validates our scientific and engineering expertise and is indicative of strong future market adoption of our technology.”

Ad is considered a leading authority in surgical treatment of atrial fibrillation, minimally invasive heart surgery, and other advanced heart surgery techniques and transcatheter therapies. He has published more than 200 research articles in peer-reviewed publications; has led the development of national and international clinical practice guidelines for different cardiovascular societies for ISMICS, AATS and STS; and serves on multiple leadership positions and committees in top cardiothoracic societies. Ad is the past president of The International Society of Minimally Invasive Cardiothoracic and Vascular Surgery (MICS), the leading entity for minimally invasive procedures globally and is the editor-in-chief of INNOVATIONS: Technology and Techniques in Cardiothoracic and Vascular Surgery.
 
“After working with the Pulse Biosciences’ team and participating in preclinical studies using the nsPFA clamp for cardiac ablation, it was immediately clear to me that nsPFA has the potential to not only replace all other energy modalities in cardiac ablation, including radiofrequency and cryo, but due to the speed, safety, and ablation performance of the system, it has the potential to significantly expand the number of patients we treat in cardiac surgery,” Ad stated. “Because of this and how far along the company is in the development of a commercially viable system, I decided to join this team as it enters this next phase of bringing nsPFA from the lab to the clinic to make a positive impact on patient lives and healthcare. I look forward to working alongside this team.”
 
Pulse Biosciences is a bioelectric medicine company whose proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is actively pursuing the development of its nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where nsPFA could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences Inc. in the United States and other countries.